30 related articles for article (PubMed ID: 35526525)
1. Proteome analysis of differential protein expression in cervical cancer cells after paclitaxel treatment.
Yim EK; Bae JS; Lee SB; Lee KH; Kim CJ; Namkoong SE; Um SJ; Park JS
Cancer Res Treat; 2004 Dec; 36(6):395-9. PubMed ID: 20368835
[TBL] [Abstract][Full Text] [Related]
2. Tephrosin Suppresses the Chemoresistance of Paclitaxel-Resistant Ovarian Cancer via Inhibition of FGFR1 Signaling Pathway.
Kim HS; Bae S; Lim YJ; So KA; Kim TJ; Bae S; Lee JH
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137377
[TBL] [Abstract][Full Text] [Related]
3. The antiviral effects of a MEK1/2 inhibitor promote tumor regression in a preclinical model of human papillomavirus infection-induced tumorigenesis.
Luna AJ; Young JM; Sterk RT; Bondu V; Schultz FA; Kusewitt DF; Kang H; Ozbun MA
Antiviral Res; 2023 Aug; 216():105667. PubMed ID: 37429527
[TBL] [Abstract][Full Text] [Related]
4. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
Zhang L; Xie D; Lei Y; Na A; Zhu L
Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
[No Abstract] [Full Text] [Related]
5. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
[TBL] [Abstract][Full Text] [Related]
6. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
[TBL] [Abstract][Full Text] [Related]
7. Targeted MEK inhibition by cobimetinib enhances doxorubicin's efficacy in osteosarcoma models.
Ma L; Xu Y; Xu X
Biochem Biophys Res Commun; 2020 Aug; 529(3):622-628. PubMed ID: 32736683
[TBL] [Abstract][Full Text] [Related]
8. Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction.
Unsworth AJ; Bye AP; Kriek N; Sage T; Osborne AA; Donaghy D; Gibbins JM
Platelets; 2019; 30(6):762-772. PubMed ID: 30252580
[TBL] [Abstract][Full Text] [Related]
9. Cobimetinib Sensitizes Cervical Cancer to Paclitaxel via Suppressing Paclitaxel-Induced ERK Activation.
Liu Y; Zhao R; Qin X; Mao X; Li Q; Fang S
Pharmacology; 2022; 107(7-8):398-405. PubMed ID: 35526525
[TBL] [Abstract][Full Text] [Related]
10. Cobimetinib (GDC-0973, XL518).
Andrlová H; Zeiser R; Meiss F
Recent Results Cancer Res; 2018; 211():177-186. PubMed ID: 30069767
[TBL] [Abstract][Full Text] [Related]
11. Cobimetinib: First Global Approval.
Garnock-Jones KP
Drugs; 2015 Oct; 75(15):1823-30. PubMed ID: 26452567
[TBL] [Abstract][Full Text] [Related]
12. Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.
Eagles JR; Jimeno A
Drugs Today (Barc); 2016 Nov; 52(11):593-605. PubMed ID: 28112278
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
